Literature DB >> 11060345

Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr.

H Liu1, C Labeur, C F Xu, R Ferrell, L Lins, R Brasseur, M Rosseneu, K M Weiss, S E Humphries, P J Talmud.   

Abstract

We have identified a G-to-A transition in exon 3 of the APOC3 gene resulting in a novel Ala23Thr apolipoprotein (apo) C-III variant, associated with apoC-III deficiency in three unrelated Yucatan Indians. The Ala23Thr substitution modifies the hydrophobic/hydrophilic repartition of the helical N-terminal peptide and hence could disturb the lipid association. In vitro expression in Escherichia coli of wild-type and mutant apoC-III enabled the characterization of the variant. Compared with wild-type apoC-III-Ala23, the mutant apoC-III-Thr23 showed reduced affinity for dimyristoylphosphatidylcholine (DMPC) multilamellar vesicles with higher amounts of free apoC-III. Displacement of apoE from discoidal apoE:dipalmitoylphosphatidycholine (DPPC) complex by apoC-III-Thr23 was comparable to wild type but the less efficient binding of the apoC-III-Thr23 to the discoidal complex resulted in a higher apoE/apoC-III (mol/mol) ratio (34%) than with wild-type/apoE:DPPC mixtures. The inhibition of lipoprotein lipase (LPL) by apoC-III-Thr23 was comparable to that of wild type, and therefore effects on LPL activity could not explain the lower triglyceride (Tg) levels in Thr-23 carriers. Thus, these in vitro results suggest that in vivo the less efficient lipid binding of apoC-III-Thr23 might lead to a faster catabolism of free apoC-III, reflected in the reduced plasma apoC-III levels identified in Thr-23 carriers, and poorer competition with apoE, which might enhance clearance of Tg-rich lipoproteins and lower plasma Tg levels seen in Thr-23 carriers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060345

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  20 in total

1.  GPIHBP1 autoantibody syndrome during interferon β1a treatment.

Authors:  Jun Eguchi; Kazuya Miyashita; Isamu Fukamachi; Katsuyuki Nakajima; Masami Murakami; Yuko Kawahara; Toru Yamashita; Yasuyuki Ohta; Koji Abe; Atsuko Nakatsuka; Mai Mino; Satoru Takase; Hiroaki Okazaki; Robert A Hegele; Michael Ploug; Xuchen Hu; Jun Wada; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2018-10-24       Impact factor: 4.766

Review 2.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

3.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

4.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

5.  Identity-by-Descent Mapping Identifies Major Locus for Serum Triglycerides in Amerindians Largely Explained by an APOC3 Founder Mutation.

Authors:  Wen-Chi Hsueh; Anup K Nair; Sayuko Kobes; Peng Chen; Harald H H Göring; Toni I Pollin; Alka Malhotra; William C Knowler; Leslie J Baier; Robert L Hanson
Journal:  Circ Cardiovasc Genet       Date:  2017-12

6.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

7.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

8.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

9.  A novel type hypertriglyceridemia observed in FLS mice.

Authors:  Masaya Takahashi; Toshiji Saibara; Yoshihisa Nemoto; Masafumi Ono; Naoaki Akisawa; Shinji Iwasaki; Katsumi Toda; Yasuhiro Ogawa; Akihiko Wakatsuki; Shuichiro Inagaki; Saburo Onishi
Journal:  Lipids       Date:  2003-07       Impact factor: 1.880

10.  Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Hu Zhou; Zhenghui G Jiang; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Daniel Figeys; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01-23       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.